What are analysts'target prices for CRISPR Therapeutics stock?
13 equities research analysts have issued 12 month target prices for Crispr Therapeutics' shares. Their predictions range from $21.00 to $72.50. On average, they expect Crispr Therapeutics' stock price to reach $57.50 in the next year.
Does CRISPR Therapeutics AG (CRSP) beat Q4 estimates?
CRISPR Therapeutics (CRSP) reports wider-than-expected Q4 loss. Nonetheless, revenues beat estimates. CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of -5.75% and 139.40%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Is there live data available for CRSP after hours?
CRSP After-Hours Quotes Live Data is currently not available After-Hours Trades Data is currently not available See More Trades Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET).
Will CRISPR Therapeutics'stock outperform the S&P 500?
MarketBeat's community ratings are surveys of what our community members think about CRISPR Therapeutics and other stocks. Vote “Outperform” if you believe CRSP will outperform the S&P 500 over the long term.
Where will CRSP stock be in 5 years?
CRISPR Therapeutics (CRSP -5.17%), a company leaning on gene-editing technology to precisely alter genomic DNA and tackle hard-to-treat diseases, is expected to see sales climb from $719,000 in 2020 to a consensus of $1.377 billion by 2025. That's an improvement of more than 191,000% in five years.
Is CRSP a buy now?
Is Crispr Therapeutics Ag Stock a good buy in 2022, according to Wall Street analysts? The consensus among 14 Wall Street analysts covering (NASDAQ: CRSP) stock is to Buy CRSP stock.
What is happening with Crispr stock?
Crispr Therapeutics Stock Shows Rising Price Performance With Jump To 94 RS Rating. Crispr Therapeutics stock saw a positive improvement to its Relative Strength (RS) Rating on Friday, rising from 90 to 94.
What is target price for CRSP?
Stock Price Target CRSPHigh$220.00Median$108.50Low$46.00Average$112.41Current Price$76.50
What is the best CRISPR stock to buy?
5 best CRISPR stocks to buyCompanyMarket CapCRISPR Therapeutics (NASDAQ:CRSP)$6.1 billionEditas Medicine (NASDAQ:EDIT)$1.9 billionIntellia Therapeutics (NASDAQ:NTLA)$8.9 billionVerve Therapeutics (NASDAQ:VERV)$1.9 billion1 more row
Is CRSP a Buy Sell or Hold?
CRISPR Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.63, and is based on 10 buy ratings, 6 hold ratings, and no sell ratings.
Will CRSP stock go up?
Stock Price Forecast The 22 analysts offering 12-month price forecasts for CRISPR Therapeutics AG have a median target of 108.50, with a high estimate of 220.00 and a low estimate of 46.00. The median estimate represents a +37.60% increase from the last price of 78.85.
What is the best genomic stock to buy?
Illumina. Illumina is the industry leader in using short-read sequencing technology, which breaks DNA into short segments to aid in analysis for genetic research, testing, and medical treatment. ... Pacific Biosciences of California. ... Exact Sciences. ... Invitae. ... Fulgent Genetics. ... Intellia Therapeutics. ... CRISPR Therapeutics.
Who won the CRISPR patent?
Nobel Prize winner Emmanuelle Charpentier, Ph. D., and two universities have officially appealed in a dispute over certain patents for CRISPR gene editing, a long-running challenge that could have wide implications for companies working on therapeutics based on the technology.
Is Crispr undervalued?
Valuation metrics show that CRISPR Therapeutics AG may be overvalued. Its Value Score of D indicates it would be a bad pick for value investors.
Why is Crispr stock low?
What happened. Shares of CRISPR Therapeutics (CRSP 0.81%) sank 50.5% in 2021, according to data from S&P Global Market Intelligence. After surging roughly 151% across 2020's trading, investors reassessed the gene-editing specialist's drug pipeline and moved out of the company's stock.
How much is Crispr worth?
CRISPR Therapeutics AG net worth as of July 22, 2022 is $5.87B.
Will CRSP stock go up?
Stock Price Forecast The 22 analysts offering 12-month price forecasts for CRISPR Therapeutics AG have a median target of 108.50, with a high estimate of 220.00 and a low estimate of 46.00. The median estimate represents a +37.60% increase from the last price of 78.85.
Is CRSP overvalued?
Our reverse cash flow model indicates that CRSP remains overvalued. Therefore, investors should consider any opportunity as highly speculative.
Is CRISPR undervalued?
Valuation metrics show that CRISPR Therapeutics AG may be overvalued. Its Value Score of D indicates it would be a bad pick for value investors.
Why is CRSP dropping?
What happened. Shares of CRISPR Therapeutics (NASDAQ: CRSP) sank 50.5% in 2021, according to data from S&P Global Market Intelligence. After surging roughly 151% across 2020's trading, investors reassessed the gene-editing specialist's drug pipeline and moved out of the company's stock.
What time is after hours trading?
About After Hours Quotes. Nasdaq provides market information on after hours trading daily from 4:15 p.m. ET to 3:30 p.m. ET on the following day.
What time do you trade after hours?
After-Hours Trades. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these sessions may offer less liquidity and inferior prices.
CRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Tops Revenue Estimates
CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of -5.75% and 139.40%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Mario Gabelli is Selling These 10 Stocks
In this article, we discuss the 10 stocks that Mario Gabelli is selling. If you want to skip our detailed analysis of Gabelli’s history, investment philosophy, and hedge fund performance, go directly to Mario Gabelli is Selling These 5 Stocks. Mario Gabelli is an Italian-American investor and hedge fund manager who founded GAMCO Investors in […]
2 Exciting Trends That Could Shape Healthcare's Future
Healthcare companies are at work on potentially groundbreaking therapies in trending areas that are being overlooked by many investors. In this segment from "This Week in Healthcare," recorded on Jan.
CRISPR Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
ZUG, Switzerland and CAMBRIDGE, Mass., Feb.
Analysts Estimate CRISPR Therapeutics AG (CRSP) to Report a Decline in Earnings: What to Look Out for
CRISPR Therapeutics AG (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards?
On CRISPR Therapeutics' (CRSP) Q4 earnings call, investor focus is likely to be on updates on the progress of the company's pipeline candidates, especially its lead candidate CTX001.
About CRISPR Therapeutics
CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA.
CRISPR Therapeutics (NASDAQ:CRSP) Frequently Asked Questions
16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CRISPR Therapeutics in the last year. There are currently 5 hold ratings and 11 buy ratings for the stock.
